S2961
Late-Breaking
ESTRO 2026
Proffered Paper 5495
When less is not enough: first results from the phase III randomized DBCG RT Natural trial Birgitte Vrou Offersen 1 , Kristine Wiborg Høgsbjerg 1 , Mette Moeller 2 , Louise Wichmann Matthiessen 3 , Mette Holck Nielsen 4 , Maja Vestmoe Maraldo 5 , Marie Benzon Mogensen 6 , Else Maae 7 , Ingvil Mjaaland 8 , Sara Alkner 9 , Egil Stoere Blix 10 , Kristin Valborg Reinertsen 11 , Unn- Miriam Kasti 12 , Cecilie Soma Nordstrand 13 , Dan Lundstedt 14 , Henrik Lindman 15 , Danijela Scepanovic 16 , Baard Mannsaaker 17 , Aase Haug 18 , Tomas Merino Lara 19 , Maj-Britt Jensen 20 , Jens Overgaard 1 1 Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. 2 Department of Oncology, Aalborg University Hospital, Aalborg, Denmark. 3 Department of Oncology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark. 4 Department of Oncology, Odense University Hospital, Odense, Denmark. 5 Department of Oncology, Zealand University Hospital Naestved, Naestved, Denmark. 6 Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 7 Department of Oncology, Sygehus Lillebaelt Vejle, Vejle, Denmark. 8 Department of Oncology, Stavanger University Hospital, Stavanger, Norway. 9 Department of Hematology, Oncology and Radiation Physicscology, Skaane University Hospital, Lund, Sweden. 10 Department of Oncology, University Hospital North Norway, Tromsoe, Norway. 11 Department of Oncology, Oslo University Hospital, Oslo, Norway. 12 Department of Oncology, Kristiansand Hospital, Kristiansand, Norway. 13 Department of Oncology, Aalesund Hospital, Aalesund, Norway. 14 Department of Oncology, Sahlgrenska Hospitall, Göteborg, Sweden. 15 Department of Oncology, Uppsala University Hospital, Uppsala, Sweden. 16 Department of radiation Oncology, National Cancer Institute of Slovakia, Bratislava, Slovakia. 17 Department of Oncology, Nordlandssykehuset, Bodoe, Norway. 18 Department of Oncology, Haukeland University Hospital, Bergen, Norway. 19 Department of Oncology, Universidad Catoloca de Chile, Santiago de Chile, Chile. 20 DBCG, Copenhagen University hospital Rigshospitalet, Copenhagen, Denmark Purpose/Objective: Radiation therapy (RT) following breast conserving surgery (BCS) is standard for breast cancer to reduce the risk of loco-regional (LRR) and distant recurrence. Increasing focus on RT omission in low-risk patients stimulated the Danish Breast Cancer Group Natural trial (NCT 03646955) testing if partial breast irradiation (PBI) could be safely omitted in selected patients. Material/Methods: The trial aimed to randomize 926 patients ( ≥ 60 years,
Conclusion: Despite increasing clinical use, AI tools in radiotherapy have undergone limited prospective evaluation (2). ARCHERY is the first multi - country trial to assess AI - based contouring and planning, particularly in settings where radiotherapy access gaps are greatest. Its robust international design supports the potential applicability of successful AI solutions across all resource settings. References: 1. Zubizarreta EH, Fidarova E, Healy B, Rosenblatt E. Need for radiotherapy in low and middle income countries - the silent crisis continues. Clin Oncol (R Coll Radiol). 2015;27(2):107-14.2. Macheka S, Ng PY, Ginsburg O, Hope A, Sullivan R, Aggarwal A. Prospective evaluation of artificial intelligence (AI) applications for use in cancer pathways following diagnosis: a systematic review. BMJ Oncol. 2024;3(1):e000255. Keywords: AI; Radiotherapy; Global Health
Made with FlippingBook - Share PDF online